Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $40.60.
Several research firms have commented on DAWN. Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th.
Get Our Latest Stock Analysis on DAWN
Insider Transactions at Day One Biopharmaceuticals
Institutional Trading of Day One Biopharmaceuticals
A number of hedge funds have recently bought and sold shares of DAWN. China Universal Asset Management Co. Ltd. increased its position in Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares during the last quarter. Quest Partners LLC bought a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $29,000. Quintet Private Bank Europe S.A. grew its holdings in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Day One Biopharmaceuticals by 87.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,066 shares of the company’s stock valued at $49,000 after purchasing an additional 1,895 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Day One Biopharmaceuticals during the second quarter valued at about $51,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.
Day One Biopharmaceuticals Trading Down 5.0 %
Day One Biopharmaceuticals stock opened at $14.96 on Wednesday. The business’s fifty day simple moving average is $15.22 and its two-hundred day simple moving average is $13.70. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $17.85. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -6.29 and a beta of -1.48.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities research analysts predict that Day One Biopharmaceuticals will post -2.66 EPS for the current year.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
- Five stocks we like better than Day One Biopharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- Comprehensive Analysis of PayPal Stock
- Investing in Travel Stocks Benefits
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Conference Calls and Individual Investors
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.